Despite advances in new modalities of cancer therapy, chemotherapy may be unavoidably used for those advanced cancer patients who fail to respond to targeted therapy and immunotherapy. Au1 show proven anticancer activities and hold promise as targeted chemotherapeutics.
Laboratory for Synthetic Chemistry and Chemical Biology (LSCCB) is an R&D centre funded by Health@InnoHK progamme of Innovation and Technology Commission of HKSAR. Established in 2020, LSCCB is operated with tripartite joint collaboration of The University of Hong Kong, Imperial College London and Peking University. LSCCB aims at integrating chemical and biomedical sciences to develop new molecular medicines and diagnostic tools for the treatment and analysis of human diseases, in particular, cancer. LSCCB currently assembles more than 20 principal investigators for 4 major research programmes including (a) Synthetic Chemistry; (b) Chemical Biology of Natural Products and Chinese Medicine; (c) Metal Anticancer Medicine, Diagnostics and Theranostics; and (d) Multi-Omics and Innovative Analytical Technologies for InnoHealth.